<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432378</url>
  </required_header>
  <id_info>
    <org_study_id>11-128</org_study_id>
    <secondary_id>5P01CA132714</secondary_id>
    <nct_id>NCT02432378</nct_id>
  </id_info>
  <brief_title>Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines</brief_title>
  <official_title>A PHASE 2 IMMUNOLOGIC EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR ADVANCED STAGE OVARIAN CANCER AND TUMOR-SPECIFIC INTRADERMAL AUTOLOGOUS ALPHA-DC1 VACCINES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIM ImmunoTech Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the immunologic and potential clinical effectiveness of intensive&#xD;
      locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel&#xD;
      followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a&#xD;
      cocktail of IP rintatolimod and interferon-alpha (IFNα) for patients with advanced stage&#xD;
      ovarian cancer (III-IV) at primary neoadjuvant setting.&#xD;
&#xD;
      In the safety phase I phase, we determined the tolerable dose of IPC-CKM. In this phase 2 we&#xD;
      will add intradermal (ID) autologous αDC1 vaccines (known to be nontoxic) to the tolerable&#xD;
      IPC-CKM regimen. The effectiveness will be determined by rate of complete pathologic&#xD;
      response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On Phase 1, patients received up to 6 cycles of IPC, with CKM after the 2nd to 6th cycles. On&#xD;
      Phase 2, patients will receive up to 6 -8 cycles of chemotherapy with ID injections of DC1&#xD;
      vaccine with CKM. To optimize the pattern of immunity, all patients will also receive oral&#xD;
      celecoxib (COX2 inhibitor).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date type="Actual">September 4, 2015</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of CD8+ tumor infiltrating T cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The difference in CD8+ tumor infiltrating T cells over 3 cycles of platinum based chemotherapy plus immunotherapy compared with baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events for the different combinations</measure>
    <time_frame>8 weeks</time_frame>
    <description>2 patients will be treated and observed for 2 cycles on each of the dose tiers to identify the acceptable dose of IFN in combination with the other protocol drugs/vaccine for the second phase of the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the number of CD3+CD8+ T cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of effector CD8+ T cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of CD4+ T cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of Tregs in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of myeloid-derived suppressor cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the number of TH1 cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of natural killer cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of dendritic cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of activated macrophages in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of tumor cells in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CCL3 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CCL4 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CCL5 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CXCL9 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CXCL10 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CXCL11 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of CXCL12 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of GrB in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of IFN gamma in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of FoxP3 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of IDO in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of NO in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of IL-10 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the concentration of COX-2 in the peritoneal fluid.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CD3+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CD4+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CD8+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CD11b+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CD11c+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of GrB+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of FoxP3+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of IDO+ cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CCL3 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CCL4 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CCL5 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CXCL9 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CXCL10 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CXCL11 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CCL22 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of CXCL12 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of GrB cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of IFN gamma cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of FoxP3 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of IDO cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of NO cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of IL-10 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in the number of COX-2 cells in the tumor tissue.</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cancer of Ovary</condition>
  <condition>Cancer of the Ovary</condition>
  <condition>Neoplasms, Ovarian</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Ovary Cancer</condition>
  <condition>Ovary Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cisplatin + Celecoxib + DC Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin + CKM + Celecoxib + DC Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cisplatin + celecoxib + DC vaccine</intervention_name>
    <description>Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle</description>
    <arm_group_label>Cisplatin + Celecoxib + DC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cisplatin + CKM + Celecoxib + DC Vaccine</intervention_name>
    <description>Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle</description>
    <arm_group_label>Cisplatin + CKM + Celecoxib + DC Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have advanced stage (III-IV) epithelial carcinoma of ovarian, tubal, or&#xD;
             peritoneal origin.&#xD;
&#xD;
               -  Histologic documentation of the original primary tumor is required via the&#xD;
                  pathology report.&#xD;
&#xD;
               -  Original tumor blocks from primary diagnosis biopsy will be reviewed by our study&#xD;
                  pathologist at Magee.&#xD;
&#xD;
               -  Patients must be receiving neoadjuvant chemotherapy&#xD;
&#xD;
          -  Patients must be eligible for cancer-related definitive therapy with neoadjuvant&#xD;
             chemotherapy&#xD;
&#xD;
          -  Patients must be chemonaive and receiving therapy in primary first line neoadjuvant&#xD;
             setting&#xD;
&#xD;
          -  Patients must have GOG performance of 0-1&#xD;
&#xD;
          -  Patients must be reasonable candidates for interval debulking surgery as well as IP&#xD;
             platinum based combination chemotherapy regimen with no prior evidence of clinically&#xD;
             significant intra-abdominal adhesions, persistent abdominal wall infections, renal&#xD;
             toxicity, or bowel obstruction.&#xD;
&#xD;
          -  Patients of childbearing potential must have a negative pregnancy test prior to the&#xD;
             study entry and be practicing an effective form of contraception. If applicable,&#xD;
             patients must discontinue breastfeeding prior to the first date of treatment on this&#xD;
             study.&#xD;
&#xD;
          -  Patient must be willing to undergo leukapheresis&#xD;
&#xD;
          -  Patients must agree to appropriate clinical monitoring to receive the study regimens.&#xD;
&#xD;
          -  Patient must have:&#xD;
&#xD;
               -  Bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) greater than or equal to 1,500/µL, equivalent to&#xD;
                  CTCAE v4 grade 1.&#xD;
&#xD;
               -  Platelets greater than or equal to 100,000/µL;&#xD;
&#xD;
               -  hemoglobin greater than or equal to 8.0 g/dL.&#xD;
&#xD;
          -  Renal function:&#xD;
&#xD;
               -  creatinine less than or equal to 1.5 x institutional upper limit normal (ULN),&#xD;
                  CTCAE v4 grade 1.&#xD;
&#xD;
          -  Hepatic function:&#xD;
&#xD;
               -  Bilirubin less than or equal to 1.5 x ULN (CTCAE v4 grade 1).&#xD;
&#xD;
               -  SGOT and alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v4 grade 1).&#xD;
&#xD;
          -  Patients who have signed informed consent and authorization permitting release of&#xD;
             personal health information.&#xD;
&#xD;
          -  Patients must be ≥ 18 years of age.&#xD;
&#xD;
          -  Patients must have a GOG Performance Status of 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with non-epithelial cancer, sarcoma or caricnosarcoma&#xD;
&#xD;
          -  Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic&#xD;
             lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis&#xD;
             (MS), ankylosing spondylitis).&#xD;
&#xD;
          -  Patients with a known allergy to cisplatin or taxane chemotherapy. Patients with&#xD;
             carboplatin allergy may be included if they tolerate a test dose of IV cisplatin given&#xD;
             in monitored floor conditions. Patients who are allergic to paclitaxel, can be&#xD;
             alternatively treated with abraxane.&#xD;
&#xD;
          -  Patients being chronically treated with immunosuppressive drugs such as cyclosporin,&#xD;
             adrenocorticotropic hormone (ACTH), or systemic corticosteroids.&#xD;
&#xD;
          -  Patients with a recognized immunodeficiency disease including cellular&#xD;
             immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients who have&#xD;
             acquired, hereditary, or congenital immunodeficiencies.&#xD;
&#xD;
          -  Patients with uncontrolled diseases other than cancer will be excluded.&#xD;
&#xD;
          -  Patients who are pregnant or nursing.&#xD;
&#xD;
          -  Patients who have contraindications to the use of NSAID's like chronic renal failure,&#xD;
             coronary artery disease, or bleeding ulcers.&#xD;
&#xD;
          -  Patients with tumors of low malignant potential, except ovarian pseudomyxoma or with&#xD;
             no peritoneal disease.&#xD;
&#xD;
          -  Patients with a history of other invasive malignancies, with the exception of&#xD;
             non-melanoma skin cancer, are excluded if there is any evidence of other malignancy&#xD;
             being present within the last five years. Patients are also excluded if their previous&#xD;
             cancer treatment contraindicates this protocol therapy.&#xD;
&#xD;
          -  Patients with previous pelvic radiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Edwards, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC CancerCenter at Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

